Results from the ASPIRE Trial: Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed Multiple Myeloma

Clinical Pearls

Shaji Kumar, MD, professor of medicine, Mayo Clinic, discusses the results of the phase III ASPIRE trial.

• This trial looked at the combination of lenalidomide and dexamethasone with or without carfilzomib for patients with relapsed multiple myeloma.
• Adding carfilzomib to lenalidomide and dexamethasone elicited an improvement in PFS.
• The combination was well tolerated.

<<<

Go back to the ASH conference page